NCI and CDMRP are awarding over $7 BILLION in funding for cancer R&D. To learn more, listen to our free webinar about these opportunities.

CDMRP announced research funding opportunities for fiscal year 2022. CDMRP aim to fund high-risk, high-gain, high-impact projects which other funding agencies may overlook and thus to fill research gaps in critical areas. The FreeMind Group hosted a webinar about these new opportunities. Get the recording, slides, and critical forms here.

Biden wishes to spend billions more on COVID-19 efforts at home and abroad. US federal funding agencies haven’t discussed specific funding opportunities based on the administration’s proposals, but it is likely there will be more funding available to biotech R&D on anti-virals, vaccines, diagnostics, etc.

The National Institute of Allergy & Infectious Diseases (NIAID) has just published a Broad Agency Announcement (BAA). This BAA contains four distinct Research Areas: Vaccines, Therapeutics, and In-Vitro Diagnostics for Biodefense, Antimicrobial Resistant Infections and Emerging Infectious Diseases, and Antivirals for Specific RNA Viral Families of Pandemic Potential.

FreeMind can help you apply for these funds or for other non-dilutive grants and contracts. FreeMind will host a webinar about the BAA on February 7, at 1:00 PM EST.

The Congressionally Directed Medical Research Programs (CDMRP), are supported by funds allocated by Congress for biomedical research in response to the needs of the American people and military. With a FY2018 budget of over $975 million, these funds will go towards supporting R&D efforts in various stages of development. Some research areas covered include Breast Cancer, Parkinson’s, and Multiple Sclerosis as well as additional Peer Reviewed topics covering Alzheimer’s, Cancer, and others.

In this webinar, we discuss the various programs, the process for applying, guidelines, key success components and insight into increasing chances for award.


View Slide Deck


NIH alone awards roughly $6B annually to Cancer related R&D grants and contracts. The scope of funding support covers much of the R&D cycle, from basic research, through pre-clinical activities and early phase clinical trials.

In this webinar, we discuss key cancer related opportunities, focusing on the new set of solicitations from the National Cancer Institute (NCI) and the soon to be released CDMRPs (DoD) that are available for life science organizations.


View Slide Deck

In a world in which both medical diagnostics and therapies are shifting towards minimally invasive technologies, it is not surprising that steadily increasing non-dilutive funding is available for innovative medical device companies.

The scope of funding support covers the entire R&D cycle, from early stage exploratory and discovery work all the way to late stage clinical research and validation.

In this webinar, FreeMind experts discuss the latest trends at the NIH and the funding opportunities available with respect to medical devices.

View Slide Deck

Non-US applicants are eligible for the majority of the non-dilutive pockets of money including NIH, Department of Defense, BARDA etc. Currently, the National Institutes of Health (NIH) are actively funding over 1000 projects in the excess of $1.3B, taking place outside the US and awarded to non-US applicant organizations. And, when taking into account collaborations and partnerships between domestic and foreign entities, the funded R&D dollars outside the US even exceed the above.

In this presentation, we provide insight into the non-dilutive funding landscape with an emphasis on the NIH, Department of Defense and other government agencies. FreeMind experts will describe the various pockets of money available for non-US applicants, potential for funding, and means to maximize chances for award.

View Slide Deck

Within the non-dilutive funding space one can find pockets of money in the billions of dollars directed at unmet medical needs related to CNS/PNS ailments. The scope of funding support covers much of the R&D cycle from proof of concept to late stage clinical.

In this webinar, we discuss key CNS/PNS related funding opportunities, with an emphasis on NINDS, NIA, and NIMH.

View Slide Deck